linjc16/ctgov huggingface dataset:
Intraopertive Hypotension and Postoperative Cardiovascular Complications Among Chinese Elderly Patients Undergoing Oncardiac Surgery : a Retrospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
To explore the relationship of intraoperative hypotension and perioperative cardiovascular complications in elderly noncardiac surgical patients

Official Title
-----------------
Intraopertive Hypotension and Postoperative Cardiovascular Complications Among Chinese Elderly Patients Undergoing Oncardiac Surgery : a Retrospective Cohort Study

Conditions
-----------------
Hypotension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 65 years Undergoing general anesthesia Inpatients who had noncardiac surgery between January 1, 2012 and August 31, 2019 Exclusion Criteria: ASA grade V Low-risk surgery (hysteroscopic and body surface surgery) Length of surgery ≤30 min Short operation interval (less than 3 days between procedures) Without intraoperative blood pressure value at 30s intervals Missing data on patient characteristics.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative cardiovascular complications |  | 2012-1 2019-8 |
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Study Overview
=================
Brief Summary
-----------------
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, X, and Y)-CRM197 Conjugate vaccine

Official Title
-----------------
A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135, X and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Conditions
-----------------
Infection, Meningococcal

Intervention / Treatment
-----------------
* Biological: EuNmCV-5
* Biological: Menveo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 19 to 55 years of age Written informed consent Available for all visits and telephone calls scheduled for the study Exclusion Criteria: Previous or suspected disease caused by N. meningitides Household and/or intimate exposure to an individual with culture-proven N. meningitides infection within 60 days prior to screening Serious acute, chronic or progressive disease as determined by investigator History of alcohol or substance abuse

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EuNmCV-5<br>Healthy adults received 0.5mL single intramuscular dose on Day 0. | Biological: EuNmCV-5<br>* 0.5mL single intramuscular dose on Day 0<br>* Other names: Meningococcal(Groups A, C, W-135, X, and Y) Conjugate Vaccine;|
| Active Comparator: Menveo<br>Healthy adults received 0.5mL single intramuscular dose on Day 0. | Biological: Menveo<br>* 0.5mL single intramuscular dose on Day 0<br>* Other names: Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of solicited adverse events | local and systemic AEs | within 7 days post vaccination | 
| Occurrence of unsolicited adverse events |  | within 28 days post vaccination | 
| Occurrence of serious adverse events |  | within 180 days post vaccination |
Discomfort in Intensive Care Patients - IPREA-N

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate discomforts experienced by intensive care patients during their critical illness period. We will use the Norwegian version of the questionnaire Inconforts des Patients de REAnimation (IPREA), the IPREA-N.Patients will be asked to rate18 questions about different possible discomforts on a 0-10 scale after their intensive care stay. Furthermore we aim to test whether the questionnaire when translated into Norwegian is useful in the Norwegian patient population. The aim of the study is to assess perceived discomfort in intensive care patients using the IPREA-N questionnaire to test psychometric properties of the questionnaire

Official Title
-----------------
Assessment of Discomfort in Intensive Care Patients and Psychometric Testing of the Applied Questionnaire IPREA-N

Conditions
-----------------
Critical Illness, Discomfort

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult intensive care patients (> 18 years), Understanding Norwegian Having spent more than 48 hours in the intensive care unit. Ability to consent to participation and self-report discomfort Exclusion Criteria: Patients who move to another hospital and cannot complete the questionnaire within 24 hours due to health status or practical reasons.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discomfort measured by IPREA-N questionnaire | IPREA-N consists of 18 Questions about discomfort during intensive care stay, answered on a 0-10 scale. Questions cover discomforts caused by noise, too much light, uncomfortable bed, lack of sleep, thirst, hunger, feeling cold, feeling hot, pain, medical devices, embarrassment, anxiety or panic, isolation, visiting hours restriction, lack of telephone, lack of information, difficulty breathing and feelings of depression, | Within 24 hours following Intensive care unit stay |
The Level of Knowledge and Awareness of Dry Needling Treatment in the Turkish Population

Study Overview
=================
Brief Summary
-----------------
The study will employ a cross-sectional design to assess the level of knowledge and awareness of dry needling therapy in the Turkish population.

Detailed Description
-----------------
A representative sample of individuals will be selected for participation in the survey. A structured questionnaire will be developed specifically for this study, consisting of questions related to the knowledge and awareness of dry needling therapy. The questionnaire will be administered through face-to-face interviews. Data collected from the survey will be analyzed using appropriate statistical methods to determine the overall level of knowledge and awareness of dry needling therapy among the Turkish population.

Official Title
-----------------
The Level of Knowledge and Awareness of Dry Needling Treatment in the Turkish Population

Conditions
-----------------
Dry Needling

Intervention / Treatment
-----------------
* Other: Dry Needling Therapy Knowledge and Awareness Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Giving consent. Exclusion Criteria: Not giving consent. Any illness or disability that can prevent filling out the form or communicating.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients admitted to the physical medicine and rehabilitation outpatient clinic.<br>Patients admitted to the physical medicine and rehabilitation outpatient clinic and gave consent to participate. | Other: Dry Needling Therapy Knowledge and Awareness Questionnaire<br>* Dry Needling Therapy Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of Knowledge and Awareness of Dry Needling Therapy in the Turkish Population | By using the data gained with the Dry Needling Therapy Knowledge and Awareness Questionnaire and using the suggested statistical methods by the statistics expert, this study will aim to determine the level of knowledge and awareness of myofascial pain syndrome in the Turkish population. | 1 day |
Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.

Study Overview
=================
Brief Summary
-----------------
Diabetic ketoacidosis (DKA), a severe complication of diabetes mellitus (DM), is the leading cause of hospitalization, morbidity and mortality in patients with DM (1). DKA is associated with hyperglycemic crises and featured by metabolic acidosis, the production of ketoacids, volume depletion, and electrolyte imbalance. Due to glucose-induced osmotic polyuria and even emesis, volume depletion is a major cause of acute kidney injury (AKI) in DKA patients (2).

Official Title
-----------------
Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.

Conditions
-----------------
Diabetic Ketoacidosis, Acute Kidney Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients will be included in this study aged >18 years old after diagnosis of AKI on top of Diabetic ketoacidosis at Sohag university hospital for all patients admitted during the period from May 2023 to May 2024 Exclusion Criteria: Chronic kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prognosis risk factors and outcomes of AKI in patients with DKA | complete resolution or progress to CKD or mortality and discover risk factors for AKI as uncontrolled diabetes infection or high uric acid uncontrolled hyperlipidemia | 1 YEAR | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DKA AKI
Microembolic Detection in Acute Ischemic Stroke Patients With Atrial Fibrillation and Outcome

Study Overview
=================
Brief Summary
-----------------
This multicenter international prospective cohort study will include patients with AIS with a known or newly diagnosed anticoagulant-naïve AF. All centers will use the same transcranial Doppler machine for one-hour monitoring with bilateral 2-MHz probes within 24 hours of symptom onset. Recordings will be analyzed for MES by a blinded central reader. The primary aim is to determine the proportion of patients with MES and the association of MES with functional outcomes assessed by a modified Rankin scale (mRS) score at 90 days.

Official Title
-----------------
Microembolic Detection in Acute Ischemic Stroke Patients With Atrial Fibrillation and Outcome - A Prospective Multicenter Study With Transcranial Doppler

Conditions
-----------------
Infarction, Brain, Embolism, Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: The presence and rate of MES measured by TCD monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute ischemic stroke admitted to the Stroke Unit, history of AF/flutter or a new diagnosis of AF at the stroke, and with a possibility to be monitored within 24 hours after symptom onset. Exclusion Criteria: use of anticoagulants at stroke onset; prosthetic valves; inadequate temporal bone window; uncooperative patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute Ischemic Stroke Patients with Atrial Fibrillation<br> | Other: The presence and rate of MES measured by TCD monitoring<br>* TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of MES |  | Within 24 hours of symptom onset | 
| Poor functional outcome |  | 90-days after stroke | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ordinal Shift Analysis of mRS scale score |  | 90-days after stroke | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infarction, Embolism, Atrial Fibrillation, Ultrasound, Transcranial Doppler
Prevalence Of Deleterious Oral Habits Among a Group of School Children in Cairo, Egypt: Cross-Sectional Study

Study Overview
=================
Brief Summary
-----------------
This study aims to detect the prevalence of practicing oral habits among a group of school children in Cairo, Egypt.

Detailed Description
-----------------
An online questionnaire utilizing the third domain of Nordic Orofacial Test screen will be distributed among school children (aged five to seven years) parents to measure the prevalence of oral habits.

Official Title
-----------------
Prevalence Of Deleterious Oral Habits Among a Group of School Children in Cairo, Egypt: Cross-Sectional Study

Conditions
-----------------
Nail Biting, Habits, Bruxism, Sucking Behavior

Intervention / Treatment
-----------------
* Other: thired domain of nordic orofcial test-screen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: school children accept to participate children within the age group Exclusion Criteria: special health care needs children

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| School children<br>school children aged from five to seven years | Other: thired domain of nordic orofcial test-screen<br>* its a questionnaire which the parent will answer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oral habits (presence / absence) | practicing one or more of the following habit(s): sucking habits, nail biting, bruxism | baseline record |
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH

Study Overview
=================
Brief Summary
-----------------
Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia

Official Title
-----------------
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Conditions
-----------------
Prostatic Neoplasms, Prostate Disease, Prostate Obstruction, Prostate Hypertrophy

Intervention / Treatment
-----------------
* Drug: Single dose tamsulosin 0.4mg
* Drug: Double dose tamsulosin 0.4mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age more than 50 years moderate to severe lower urinary tract symptoms Exclusion Criteria: prostatic cancer urethral stricture prostate surgery Neurogenic bladder

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Single dose tamsulosin 0.4mg<br>Single dose tamsulosin 0.4mg | Drug: Single dose tamsulosin 0.4mg<br>* Single dose tamsulosin 0.4mg<br>|
| Active Comparator: Double dose tamsulosin 0.4mg<br>Double dose tamsulosin 0.4mg | Drug: Double dose tamsulosin 0.4mg<br>* Double dose tamsulosin 0.4mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the lower urinary tract symptoms | Assessed by the improvement in the internal prostatic symptoms score (IPSS) | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tamsulosin, Prostate
Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism

Study Overview
=================
Brief Summary
-----------------
Eight healthy male volunteers will be studied in consecutive sessions regarding the acute effect of evolocumab and atorvastatin on cholesterol and bile metabolism.

Official Title
-----------------
Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism

Conditions
-----------------
Acute Metabolic Effects of Evolocumab and Atorvastatin

Intervention / Treatment
-----------------
* Drug: Evolocumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male >18 years of age Exclusion Criteria: Cardiovascular disease Cerebrovascular disease (e.g. stroke, prior aneurysm) Pulmonary disease (e.g. pulmonary hypertension, COPD) Metabolic disease (incl. but not limited to Cushing disease, Diabetes) Renal disease (by Chronic kidney disease criteria) Active inflammatory bowel syndrome Cancer Pregnancy Smoker Any chronic medication use Steroid treatment for the last six months or hormone replacement therapy Coagulopathy Musculoskeletal or neurologic disease Know allergy against any of the studied substances Inclusion in any other concurrent medical research study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Full group<br>Evolocumab 140 mg subcutaneously. Två months later, repetitive doses of atorvastatin 40 mg once daily. After continued atorvastatin, evolocumab 140 mg is added subcutaneously. | Drug: Evolocumab<br>* See arm description<br>* Other names: Atorvastatin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cholesterol metabolism effect | Effect of these treatments on markers for cholesterol metabolism, namely lathosterol and campesterol, measured as change from baseline concentration (mg/mmol) per unit time. | 32 hours | 
| Bile acid metabolism effect | Effect of these treatments on markers for bile acid metabolism, namely C4; measured as change from baseline concentration (mg/mmol) per unit time. | 32 hours | 
| Bile acid metabolism effect | Effect of these treatments on markers for cholesterol and bile acid metabolism, namely bile acids; measured as change from baseline concentration (mikromol/ml) per unit time. | 32 hours |
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction

Study Overview
=================
Brief Summary
-----------------
This study is a multicenter cohort study including patients diagnosed with aortic valve disease during hospitalization, including aortic insufficiency and aortic valve stenosis. The primary outcome of the study was all-cause death, and the secondary outcome was cardiovascular events. Through follow-up observation, the prognostic risk factors of patients with aortic disease were evaluated, and a prognostic model was constructed to guide clinical decision-making.

Official Title
-----------------
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction (ARISTOTLE)

Conditions
-----------------
Aortic Valve Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 diagnosed as aortic valve disease Exclusion Criteria: aortic valve replacement at baseline

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality | death caused by any cause | from baseline to death or end of follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular death | Death caused by cardiac causes | from baseline to death or end of follow-up | 
| Aortic valve replacement | Transcatheter aortic valve replacement or surgical aortic valve replacement | from baseline to aortic valve replacement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aortic stenosis, aortic valve insufficiency, risk factor, prediction model